Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues	$ 23	$ 50	$ 23	$ 54
Cost of revenues	(1)	(2)	(1)	(2)
Gross profit	22	48	22	52
Operating Expenses:
Research and development expenses	(5,572)	(7,432)	(11,398)	(15,197)
Less: participation by the Israeli Innovation Authority (IIA), Horizon 2020 and other parties	932	1,176	1,376	2,177
Research and development expenses, net	(4,640)	(6,256)	(10,022)	(13,020)
General and administrative expenses, net	(1,750)	(2,123)	(3,563)	(4,333)
Operating loss	(6,368)	(8,331)	(13,563)	(17,301)
Financial income (expense), net	(2)	(352)	54	(168)
Net loss for the period	$ (6,370)	$ (8,683)	$ (13,509)	$ (17,469)
Loss per share:
Basic and diluted net loss per share	$ (0.40)	$ (0.75)	$ (0.86)	$ (1.52)
Weighted average number of shares used in computing basic and diluted net loss per share	15,927,749	11,579,093	15,665,641	11,472,336